8% (10/260) compared with 6.8% (87/1283) in 2001. Regular analgesic users also provided information about their current and past medical conditions. Based on the compound last used, a higher proportion of NSAID users were likely to either currently or previously have been affected by a medical condition that posed a contraindication, warning or precaution to the use of that CYC202 price compound compared to paracetamol users (Table 4). The

proportion of respondents with a medical condition (current or previous) that is listed as a contraindication, warning or precaution to NSAID use increased significantly from 2001 to 2009 (Table 4). There was no significant increase among the paracetamol users. Overall, the suitability rate was significantly higher among paracetamol users than for NSAID users in both 2001 (98.3 compared with 79.3%; P < 0.05) and 2009 (96.4 compared with 69.1%; P < 0.05; Figure 3). Regular analgesic users also provided information PD-0332991 price about current use of other medications. In 2009, based on the compound last used, 13.6% (35/260) of regular NSAID users reported taking another, concurrent, medication that might put them at increased risk of drug–drug interactions or adverse events; 1.6% fewer than in 2001. In 2009, 7.5% (20/260) of regular NSAID users were using another NSAID [OTC (n = 18) or prescribed (n = 2)] concurrently with OTC ibuprofen, 4.4% (12/260) were also taking antihypertensive medications and 1.3% (3/260) were

also taking combination antihypertensive agents. The proportion of people at risk of potential drug–drug interactions was significantly lower among regular paracetamol users than regular NSAID users (Table 4). The medical conditions that were most frequently implicated as making the analgesic use potentially unsuitable were asthma and gastrointestinal complications (NSAID users) and liver and renal disease (paracetamol users). In 2009, 10.0% (26/260) of regular NSAID users stated that they had currently diagnosed asthma and 25.0% (65/260) stated that they had ever been diagnosed with asthma, an increase from 3% (8/255) and 15% (38/255),

respectively, in 2001. Similarly, in 2009, 6.2% (16/260) of regular NSAID users had currently diagnosed gastrointestinal conditions Etofibrate (compared with 2.3%, 6/255, in 2001) and 23.1% (60/260) had ever been diagnosed with a gastrointestinal condition (compared with 11.0%, 28/255, in 2001). Among the 624 regular users of OTC paracetamol, six (1.0%) reported currently having liver disease and 13 (2.0%) reported ever having had this condition. By comparison, in 2001 no regular paracetamol user reported current liver disease and 15 (2.0%) reported ever having had liver disease. At the time of the 2009 survey, 78 women were pregnant, breastfeeding or trying to conceive. Almost two-thirds (48, 61.5%) of these women were categorised as regular OTC analgesic users and, of these, 34 (70.8%) had used paracetamol on the last occasion and 14 (29.